Abstract
s / Drug and Alcohol Dependence 146 (2015) e118–e201 e177 increases in SOWS and OOWS scores (P<0.05). Certain HMO:NAL ratios showed significantly lower effects on most PD end-points, including Drug Liking VAS (P<0.05), compared to HMO alone. Conclusions: In this population the IV co-administration of naloxone with HMO had its intended effect of reducing abuserelated opioid effects and inducingwithdrawal symptoms; thereby potentially deterring abuse in opioid-dependent subjects. Such a product may have important public health benefits by reducing high-risk IV abuse of prescription opioids intended for oral administration, while continuing to provide pain relief. Financial support: Study was funded by Purdue Pharma (Canada). http://dx.doi.org/10.1016/j.drugalcdep.2014.09.396 Characterizing sex differences among pain medication abusers Ben Lewis, Lauren Hoffman, Sara J. Nixon Psychiatry, University of Florida, Gainesville, FL,
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have